Zamarin D

ORCID: 0000-0002-0094-0161 · 3 papers in corpus
other 2023
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283
Gynecologic Oncology ·doi:10.1016/j.ygyno.2023.06.021

OBJECTIVE: Gynecologic cancers are traditionally managed according to their presumed site of origin, without regard to the underlying histologic subtype. Clear cell histology is associated with chemotherapy refractoriness and poor survival.…

2022
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society ·doi:10.1136/ijgc-2022-003430

BackgroundAlthough immune checkpoint blockade has demonstrated limited effectiveness against ovarian cancer, subset analyses from completed trials suggest possible superior efficacy in the clear cell carcinoma subtype.ObjectiveTo describe t…

2017
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Annals of oncology : official journal of the European Society for Medical Oncology ·doi:10.1093/annonc/mdx525

BackgroundWe sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or ovarian clear cell cancer (OCCC) using a national database.Patients and m…